Mereo BioPharma reported net income of -$7.00M for the quarter ended Jun 2026. This income statement covers 24 quarters of results from Dec 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2017 | Dec2018 | Jun2019 | Dec2019 | Jun2020 | Dec2020 | Jun2021 | Dec2021 | Jun2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 67.79M | 116.98M | 124.99M | 124.99M | 128.64M | 140.24M | 140.26M | 140.27M | 153.85M | 155.15M | 159.00M | 159.00M | 159.10M | 159.13M | 159.62M | 159.62M | 159.69M | |||||||
| Revenue & cost | ||||||||||||||||||||||||
| Revenue | 9.00M | 1.00M | 0.50M | |||||||||||||||||||||
| Gross Profit | -0.35M | 5.57M | -0.23M | 1.27M | 0.37M | |||||||||||||||||||
| Operating items | ||||||||||||||||||||||||
| Research & DevelopmentR&D | 5.31M | 3.71M | 3.59M | 4.80M | 3.99M | 4.95M | 3.17M | 8.82M | 3.93M | 5.37M | 4.27M | 4.19M | 4.75M | 1.81M | ||||||||||
| Selling, General & AdministrativeSG&A | 6.45M | 2.67M | 5.71M | 3.60M | 5.91M | 7.87M | 6.20M | 6.45M | 7.27M | 5.49M | 6.04M | 4.20M | 4.02M | 5.22M | ||||||||||
| Other Operating ExpensesOther Opex | -5.63M | -1.69M | -4.12M | 3.29M | 2.05M | 0.03M | ||||||||||||||||||
| Operating ExpensesOpex | 11.76M | 6.38M | 9.30M | 8.40M | 9.90M | 12.81M | 9.37M | 15.28M | 11.20M | 10.87M | 10.31M | 8.39M | 8.77M | 7.03M | ||||||||||
| Operating IncomeOp. Inc | -11.41M | -0.81M | -9.07M | -7.13M | -9.90M | -12.81M | -9.37M | -15.28M | -11.20M | -10.50M | -10.02M | -8.39M | -8.77M | -7.03M | ||||||||||
| EBIT | -11.41M | -0.81M | -9.07M | -7.13M | -9.90M | -12.81M | -9.37M | -15.28M | -11.20M | -10.50M | -10.02M | -8.39M | -8.77M | -7.03M | ||||||||||
| Non-operating items | ||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.80M | 1.03M | 0.70M | 0.35M | 0.31M | 0.33M | 0.35M | 0.38M | 0.18M | 0.02M | 0.03M | 0.02M | 0.02M | 0.02M | ||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.31M | 0.37M | 0.69M | 0.76M | 0.62M | 0.56M | 0.98M | 0.88M | 0.66M | 0.59M | 0.50M | 0.42M | 0.33M | 0.28M | ||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.54M | -0.10M | -0.20M | -0.45M | -0.07M | -0.06M | 0.16M | 0.42M | -0.10M | 0.20M | 0.29M | 0.02M | 0.01M | |||||||||||
| Net income details | ||||||||||||||||||||||||
| EBT | -12.08M | -1.75M | -6.53M | -9.64M | -8.95M | -12.26M | -15.00M | -7.05M | -12.89M | -14.62M | -7.02M | -7.35M | -6.72M | -7.00M | ||||||||||
| Tax ProvisionsTaxes | -0.53M | 10.86M | 10.41M | |||||||||||||||||||||
| Profit After TaxPAT | -12.08M | -1.75M | -10.11M | -9.11M | -8.95M | -12.26M | -15.00M | -8.41M | -12.89M | -14.62M | -9.29M | -7.35M | -6.72M | -7.00M | ||||||||||
| Income from Continuing OperationsIncome (Continuing) | -12.08M | -1.75M | -6.53M | -9.11M | -8.95M | -12.26M | -15.00M | -17.91M | -12.89M | -14.62M | -7.02M | -17.77M | -6.72M | -7.00M | ||||||||||
| Consolidated Net IncomeConsol Net Inc. | -12.08M | -1.75M | -6.53M | -9.11M | -8.95M | -12.26M | -15.00M | -17.91M | -12.89M | -14.62M | -7.02M | -17.77M | -6.72M | -7.00M | ||||||||||
| Income towards Parent CompanyParent Net Inc | -12.08M | -1.75M | -6.53M | -9.11M | -8.95M | -12.26M | -15.00M | -17.91M | -12.89M | -14.62M | -7.02M | -17.77M | -6.72M | -7.00M | ||||||||||
| Net Income towards Common StockholdersNet Income | -12.08M | -1.75M | -6.53M | -9.11M | -8.95M | -12.26M | -15.00M | -17.91M | -12.89M | -14.62M | -7.02M | -17.77M | -6.72M | -7.00M | ||||||||||
| Additional items | ||||||||||||||||||||||||
| EPS (Basic) | -0.10 | -0.01 | -0.05 | -0.07 | -0.06 | -0.09 | -0.10 | -0.12 | -0.08 | -0.09 | -0.04 | -0.11 | -0.04 | -0.04 | ||||||||||
| EPS (Diluted) | -0.10 | -0.01 | -0.05 | -0.07 | -0.06 | -0.09 | -0.10 | -0.12 | -0.08 | -0.09 | -0.04 | -0.11 | -0.04 | -0.04 | ||||||||||
| Shares Outstanding | 17.88M | 67.79M | 67.79M | 105.56M | 105.56M | 120.64M | 124.79M | 125.68M | 136.99M | 131.89M | 140.05M | 142.35M | 154.03M | 147.92M | 156.86M | 159.89M | 159.99M | 159.42M | 160.36M | 160.71M | ||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 17.88M | 67.79M | 67.79M | 111.06M | 111.06M | 120.64M | 124.79M | 125.68M | 136.99M | 131.89M | 140.05M | 142.35M | 154.03M | 147.92M | 156.86M | 159.89M | 159.99M | 159.42M | 160.36M | 160.71M | ||||
| EBITDA | -11.41M | -0.81M | -9.07M | -7.13M | -9.90M | -12.81M | -9.37M | -15.28M | -11.20M | -10.50M | -10.02M | -8.39M | -8.77M | -7.03M | ||||||||||
| Interest ExpensesInt Expense | 0.80M | 1.03M | 0.70M | 0.35M | 0.31M | 0.33M | 0.35M | 0.38M | 0.18M | 0.02M | 0.03M | 0.02M | 0.02M | 0.02M | ||||||||||
| Tax Rate | 5.52 | -154.17 | -141.67 |